Rajeev Venkayya, Aerium Therapeutics CEO
In year 3 of the pandemic, a new Covid-19 biotech takes flight with an antibody combo and Takeda's ex-vaccines chief at the helm
Year three of the Covid-19 pandemic just began, but this far in, Omega Funds thinks it’s not too late to launch a biotech to fight …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
